These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19917362)

  • 41. The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients.
    Scarsi M; Bossini N; Malacarne F; Valerio F; Sandrini S; Airò P
    Transpl Int; 2010 Aug; 23(8):786-95. PubMed ID: 20136785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques - an experimental study.
    Berglund E; Alonso-Guallart P; Danton M; Sellberg F; Binder C; Fröbom R; Berglund D; Llore N; Sakai H; Iuga A; Ekanayake-Alper D; Reimann KA; Sachs DH; Sykes M; Griesemer A
    Transpl Int; 2020 Jan; 33(1):98-107. PubMed ID: 31523849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone.
    Tornatore KM; Reed K; Venuto RC
    J Med; 1993; 24(2-3):98-112. PubMed ID: 8105017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
    Papp KA; Gooderham MJ; Girard G; Raman M; Strout V
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
    Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH
    Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.
    Li J; Zhou B; Shentu J; Du L; Tan M; Hou S; Qian W; Li B; Zhang D; Dai J; Wang H; Zhang X; Chen J; Guo Y
    MAbs; 2010; 2(4):449-56. PubMed ID: 20519962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
    Friend PJ; Rebello P; Oliveira D; Manna V; Cobbold SP; Hale G; Jamieson NV; Jamieson I; Calne RY; Harris DT
    Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
    [No Abstract]   [Full Text] [Related]  

  • 49. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.
    Goldberg A; Geppert T; Schiopu E; Frech T; Hsu V; Simms RW; Peng SL; Yao Y; Elgeioushi N; Chang L; Wang B; Yoo S
    Arthritis Res Ther; 2014 Feb; 16(1):R57. PubMed ID: 24559157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
    Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
    J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects.
    Martinsson-Niskanen T; Riisbro R; Larsson L; Winstedt L; Stenberg Y; Pakola S; Stassen JM; Glazer S
    Clin Ther; 2011 Sep; 33(9):1142-9. PubMed ID: 21906811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
    Yu XQ; Robbie GJ; Wu Y; Esser MT; Jensen K; Schwartz HI; Bellamy T; Hernandez-Illas M; Jafri HS
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
    Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
    Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies.
    Delmonico FL; Knowles RW; Colvin RB; Cavender DE; Kawai T; Bedle M; Stroka D; Preffer FI; Haug C; Cosimi AB
    Transplant Proc; 1993 Feb; 25(1 Pt 1):784-5. PubMed ID: 8438479
    [No Abstract]   [Full Text] [Related]  

  • 58. An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis.
    Zhao Q; Chen X; Jiang J; Li J; Zhong W; Han H; Li Z; Leung SO; Zhang F; Hu P
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):691-704. PubMed ID: 34423769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen.
    Meijer RT; Koopmans RP; ten Berge IJ; Schellekens PT
    J Pharmacol Exp Ther; 2002 Jan; 300(1):346-53. PubMed ID: 11752135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BTI-322 for acute rejection after renal transplantation.
    Mourad M; Besse T; Malaise J; Baldi A; Latinne D; Bazin H; Pirson Y; Hope J; Squifflet JP
    Transplant Proc; 1997 Aug; 29(5):2353. PubMed ID: 9270759
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.